Jiangsu Hengrui Pharmaceuticals (HKG:1276) received Chinese regulatory approval to begin clinical trials of two experimental medicines, according to Hong Kong bourse filings Wednesday.
Shares of the pharma company rose over 2% in morning trade Thursday.
The company said it secured the National Medical Products Administration's nod to study SHR-2173 as a treatment for primary membranous nephropathy, an autoimmune kidney disease.
Meanwhile, the regulator also approved Jiangsu's request to evaluate HRS-9821 in chronic obstructive pulmonary disease, a lung condition.
Clinical trials for both drugs will begin in the near future, the firm said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。